Prakt. lékáren. 2009; 5(6): 263-265 [Klin Farmakol Farm. 2009;23(3):148-150]

Rivaroxaban in prevention of tromboembolism after major orthopedic surgeries

doc.MUDr.Karel Urbánek, Ph.D.1, MUDr.Jiří Gallo, Ph.D.2
1 Ústav farmakologie LF UP a FN Olomouc
2 Ortopedická klinika LF UP a FN Olomouc

Rivaroxaban is an oral selective, direct factor Xa inhibitor. It has well predictable pharmacodynamics and pharmacokinetics and is generally

well tolerated. Rivaroxaban is used in patients undergoing knee and hip arthroplasty as a prevention of deep vein thrombembolism

in the dose 10 mg once daily as long as the risk of venous thromboembolism persists (in elective hip replacements for 5 weeks). In clinical

trials, rivaroxaban showed a significant reduction in the incidence of venous thromboembolism as compared with enoxaparin.

Keywords: rivaroxaban, venous thrombembolism, hip arthroplasty, knee arthroplasty

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek K, Gallo J. Rivaroxaban in prevention of tromboembolism after major orthopedic surgeries. Praktické lékárenství. 2009;5(6):263-265.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007; 89(6): 799-807. Go to original source... Go to PubMed...
    2. Pellegrini VD Jr, Sharrock NE, Paiement GD, Morris R, Warwick DJ. Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment. Instr Course Lect. 2008; 57: 637-661. Go to PubMed...
    3. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does Aspirin Have a Role in Venous Thromboembolism Prophylaxis in Total Knee Arthroplasty Patients? J Arthroplasty. 2009 Aug 11. [Epub ahead of print]. Go to original source... Go to PubMed...
    4. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78(4): 412-421. Go to original source... Go to PubMed...
    5. Piccini JP, Patel MR, Mahaffey KW, et al. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008; 17: 925-937. Go to original source... Go to PubMed...
    6. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-226. Go to original source... Go to PubMed...
    7. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-990. Go to original source... Go to PubMed...
    8. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775. Go to original source... Go to PubMed...
    9. Kakkar AK, Brenner B, Dahl OE, et al. (RECORD2 Investigators) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372(9632): 31-39. Go to original source... Go to PubMed...
    10. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. Go to original source... Go to PubMed...
    11. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91(5): 636-644. Go to original source... Go to PubMed...
    12. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373(9676): 1673-1680. Go to original source... Go to PubMed...
    13. ##
    14. Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr. Med. Chem. 2007; 14: 2471-2481. Go to original source... Go to PubMed...
    15. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Week 2009; 139: 60-64.
    16. Haas S. New anticoagulants - towards the development of an, ,ideal" antikoagulant. VASA-J Vascul Dis 2009; 38: 13-29. Go to original source...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.